Hosted on MSN

ProPhase Labs signals $50M net collection target and strategic initiatives as Crown Medical litigation advances

Ted Karkus, Chairman & CEO, opened by emphasizing the critical importance of shareholder voting on the company's proxy, noting, "If you do not vote for our proxy, you are putting our company in harm's ...
Nasdaq

ProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

UNIONDALE, NY, June 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced ...
Seeking Alpha

ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025

UNIONDALE, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (PRPH), (the “Company” or “ProPhase”) a diversified diagnostics, genomics, and consumer healthcare company, today reported ...
Nasdaq

ProPhase Labs Posts Narrower Q2 Loss

ProPhase Labs develops and markets over-the-counter health supplements and diagnostic tools. Its product lineup includes dietary supplements for consumer health and the BE-Smart™ esophageal cancer ...
Morningstar

ABL Diagnostics Informs the Market of a Non‑Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger

ABL Diagnostics Informs the Market of a Non‑Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger The contemplated transaction remains subject to due ...